Nuvation Bio announced that it has amended its exclusive license agreement with Daiichi Sankyo to add Japan rights for safusidenib, a brain‑penetrant IDH1 inhibitor in late‑stage development. The amendment gives Nuvation full global development and commercialization rights, allowing the company to extend its pivotal SIGMA Phase 3 study into the Japanese market and to use all existing and future data for regulatory filings and publications.
The deal removes the previous restriction that Daiichi Sankyo retained Japan rights, consolidating global rights under Nuvation. By adding Japan, the company can collect data from Japanese patients and incorporate those results into the global dataset, which is essential for regulatory submissions in both the United States and Japan. The amendment also provides a potential source of non‑dilutive capital through milestone payments, a valuable benefit given the company’s recent net losses.
Safusidenib has shown encouraging results in Phase 1 and Phase 2 studies. A Phase 2 study published in Neuro‑Oncology (November 2025) reported data with a March 10 2023 cut‑off, and as of February 2026, 12 patients remained on treatment. The Phase 1 study in Japan enrolled 47 participants with recurrent or progressive IDH1‑mutant glioma, providing early evidence of safety and activity in the Japanese population.
Securing Japan rights positions Nuvation to tap a significant share of the global glioma market, potentially increasing the drug’s commercial reach. The expanded rights also simplify the company’s development strategy, allowing a more coordinated global launch if the Phase 3 results are positive. Analysts view the expanded rights as a meaningful upside to the company’s pipeline, reflecting confidence in Nuvation’s strategy to consolidate global rights and accelerate safusidenib’s development.
CEO David Hung said, "With this agreement now final, we plan to expand the pivotal Phase 3 SIGMA study into Japan, continue to advance the robust global development of safusidenib, and pursue presentation and publication of longer‑term data from the Phase 2 study to ensure the scientific community is up to date on these findings."
The licensing deal was well received by investors, reflecting confidence in Nuvation’s strategy to consolidate global rights and accelerate safusidenib’s development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.